NeoTract today touted a reimbursement win from Geisinger Health Plan and EmblemHealth that will allow coverage for procedures using its UroLift system for patients with benign prostatic hyperplasia.
The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate.
Geisinger Health Plan serves 540,000 members in Pennsylvania, New Jersey, Delaware, Main and West Virginia, while EmblemHealth serves New York, New Jersey and Connecticut.
“We are pleased to see the continued expansion of access to UroLift for millions of men across the United States who are seeking this much less invasive treatment for BPH. That integrated healthcare systems such as Geisinger, Kaiser Permanente, and Select Health have all embraced UroLift system treatment is not only a testament to the improved net health outcomes UroLift offers, but also the efficiency of care the treatment can provide a healthcare system,” prez & CEO Dave Amerson said in a press release.
In July, Neotract said it logged several reimbursement wins for its UroLift treatment for enlarged prostates, including a Medicare contractor and at least 7 independent insurers.
The Centers for Medicare & Medicaid Services granted coverage for UroLift effective Jan. 1, 2015. In May, NeoTract released data from 2 randomized UroLift studies, touting “excellent” durability after 4 years.
